| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Tetrabenazine Metabolite targets the vesicular monoamine transporter 2 (VMAT2) with high affinity, exhibiting a Ki of 13.4 nM. By inhibiting VMAT2, it reduces the uptake of monoamines (dopamine, serotonin, and norepinephrine) into synaptic vesicles, thereby depleting monoamine stores and reducing their release.
|
|---|---|
| ln Vitro |
In vitro, Tetrabenazine Metabolite demonstrates potent VMAT2 inhibitory activity with a Ki of 13.4 nM. Its activity is confirmed in radioligand binding assays, where it displaces [3H]DHTBZ from VMAT2 in rat striatal membranes. It is highly selective for VMAT2 over other monoamine transporters.
|
| ln Vivo |
In vivo, Tetrabenazine Metabolite is the active form of tetrabenazine and is responsible for its therapeutic effects. It is used in the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders. It is also studied in animal models for its effects on monoamine depletion and motor function.
|
| Enzyme Assay |
The in vitro VMAT2 binding assay for Tetrabenazine Metabolite involves incubating the compound with rat striatal membranes and a radiolabeled ligand, such as [3H]DHTBZ. The amount of radioligand displaced is measured, and the Ki is calculated from the competition binding curve.
|
| Cell Assay |
In vitro cell-based assays for Tetrabenazine Metabolite are not typically performed, as its primary target is the VMAT2 transporter. However, its effects on monoamine uptake can be studied in cells expressing VMAT2, where the inhibition of [3H]dopamine uptake is measured.
|
| Animal Protocol |
In vivo animal experiments for Tetrabenazine Metabolite are performed in models of hyperkinetic disorders, such as the reserpine-induced or MPTP-induced models in rodents. The compound is administered, and its effects on motor activity and monoamine levels in the brain are assessed.
|
| ADME/Pharmacokinetics |
Tetrabenazine Metabolite has a molecular weight of 319.44 g/mol and is soluble in DMSO. It is typically stored as a powder at -20°C for up to 3 years. In solution, it is stable at -80°C for 1 year.
|
| Toxicity/Toxicokinetics |
In vitro, Tetrabenazine Metabolite is a potent VMAT2 inhibitor with a Ki of 13.4 nM. As a research compound, it is not intended for human use, and comprehensive toxicity studies have not been reported. Standard safety precautions for handling chemical reagents should be followed.
|
| References | |
| Additional Infomation |
Tetrabenazine Metabolite is a research compound with no clinical approval as a stand-alone drug. It is the active metabolite of tetrabenazine, which is approved for the treatment of chorea associated with Huntington's disease. It is a valuable tool for studying VMAT2 biology and for developing new treatments for hyperkinetic disorders.
|
| Molecular Formula |
C19H29NO3
|
|---|---|
| Molecular Weight |
319.43846
|
| Exact Mass |
319.215
|
| CAS # |
924854-60-4
|
| PubChem CID |
14580382
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.13±0.1 g/cm3 (20 °C, 760 mmHg)
|
| Boiling Point |
457.8±45.0 °C (760 mmHg)
|
| LogP |
2.967
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
389
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C(C1CN2CCC3C(C2CC1O)=CC(OC)=C(OC)C=3)C(C)C
|
| InChi Key |
WEQLWGNDNRARGE-OIISXLGYSA-N
|
| InChi Code |
InChI=1S/C19H29NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16-17,21H,5-7,10-11H2,1-4H3/t14-,16-,17+/m1/s1
|
| Chemical Name |
(2S,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1305 mL | 15.6524 mL | 31.3048 mL | |
| 5 mM | 0.6261 mL | 3.1305 mL | 6.2610 mL | |
| 10 mM | 0.3130 mL | 1.5652 mL | 3.1305 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
